230 episodes

STAT’s weekly biotech podcast, breaking down the latest news, digging deep into industry goings-on, and giving you a preview of the week to come.

The Readout Loud STAT

    • Business
    • 4.6 • 258 Ratings

STAT’s weekly biotech podcast, breaking down the latest news, digging deep into industry goings-on, and giving you a preview of the week to come.

    228: A surprise success in Alzheimer's and how FDA history seeded modern controversy

    228: A surprise success in Alzheimer's and how FDA history seeded modern controversy

    Lecanemab, a new Alzheimer's treatment from partners Biogen and Eisai, succeeded in a pivotal clinical trial, and we explain the surprising development and its sweeping implications. Then, oncologist Mikkael Sekeres joins us to talk about his new book, which is a history of the FDA and an insider’s look at one of the agency’s most contentious drug approval hearings.

    • 35 min
    227: Biden's Covid declaration, twilight of the SPAC, & genome editing 2.0

    227: Biden's Covid declaration, twilight of the SPAC, & genome editing 2.0

    Heidi Tworek, a professor at the University of British Columbia and expert on public health communication, joins us to discuss President Biden's declaration that "the pandemic is over" and how leaders around the world are talking about Covid-19 as it enters its third year. We’ll also discuss the latest news in the life sciences, including the twilight of the SPAC boom, the coming evolution of genome editing, and the next big trial in Alzheimer’s disease.

    • 34 min
    226: Pharma's telehealth gold mine, the return of the biotech IPO, & a merger deferred

    226: Pharma's telehealth gold mine, the return of the biotech IPO, & a merger deferred

    Our colleague Katie Palmer joins us to explain a burgeoning trend in pharmaceutical advertising that has health policy experts alarmed. We also discuss the White House's investment in biotech, a bellwether IPO, and the latest twist in the Merck-Seagen saga.

    • 27 min
    225: Illumina's $8 billion limbo, a new treatment for ALS, & Emirati biotech funding

    225: Illumina's $8 billion limbo, a new treatment for ALS, & Emirati biotech funding

    Our colleague Matthew Herper joins us to discuss how Illumina, the biggest company in genomic sequencing, got into an $8 billion predicament. We also discuss a dramatic development for a new ALS treatment, the latest in cancer research, and a well-funded new player in biotech venture capital.

    • 33 min
    224: The anti-aging research boom, the Godfather of biotech, & the future of Biogen

    224: The anti-aging research boom, the Godfather of biotech, & the future of Biogen

    Our colleague Megan Molteni joins us to explain the scientific discoveries, rampant hype, and Silicon Valley billions behind the burgeoning field of longevity research. Then, we discuss the remarkable career of Stelios Papadopoulos, the venerated Godfather of biotech who faces the daunting task of saving Biogen.

    • 34 min
    223: Fauci's non-retirement, grading biotech VCs, & a bellwether IPO

    223: Fauci's non-retirement, grading biotech VCs, & a bellwether IPO

    Our colleague Helen Branswell joins to explain the Covid-19 booster debate, the Biden Administration’s monkeypox response, and the long career of the soon-to-step-down Anthony Fauci. We also discuss the latest news in the life sciences, including a milestone for gene therapy, the tentative return of an IPO market, and the venture capital league table.

    • 30 min

Customer Reviews

4.6 out of 5
258 Ratings

258 Ratings

ocean 1435🐾 ,

Love this

Hi i love the podcast❤️❤️❤️❤️❤️❤️

reportinghygeine ,

Wrong Tone On the Murder for Hire

It sounds like someone was killed. If it was one of your close relatives you would be furious about the tone. Murder is serious, not funny, although I do understand that it’s not usually your beat. You come off as young, naive and lacking in character and wisdom.

CxxxxLxxxxx ,

Great for people who follow the biotech industry

Does a great job of reporting on and discussing the important developments in the biotech industry.

You Might Also Like

Timmerman Report
BioCentury
Tradeoffs
Vincent Racaniello
STAT
Vincent Racaniello